Advancing the Bio-based Economy: What’s Needed to Drive Policy Change and Unleash Investment?

- Frank Flora, Chair, Biobased Products Coordination Council (BPCC) of USDA (Beltsville, MA)
- Dr. George Michalakisyn, Director, Life Sciences Branch, Industry Canada (Ottawa, ON)

Cancer

Congress Hall G

Our understanding of the biology and genetics of cancer has increased dramatically over the past 25 years. Despite the wealth of research initiatives and innovative new treatments, a “cure” for cancer is still not in our grasp. However, recent investments by governments and the private sector prove that cancer still remains a major issue and a worldwide priority. Our panel of speakers for this session will discuss new technology platforms and present new research findings in the research and treatment of cancer.

Moderator:
Dr. William P. Peters, Chief Executive Officer and Vice Chairman, Adhesives Technologies Inc. (Ottawa, ON)

- Oncolytic Viruses: A Platform for Treatment and Genetic Therapy
  Dr. John Bell, Associate Scientist, Cancer Therapeutics, Ottawa Health Research Institute (Ottawa, ON)
- Advancing Melanoma Cancer Research
  Dr. Elaine Jacobson, Professor, University of Arizona Cancer Centre
- Canada’s Cancer Research Priorities
  Dr. Philip Branton, Scientific Director, CIHR Institute of Cancer Research (Montreal, QC)
- Topic to be announced
  Dr. Maureen O’Connor, Cancer Genomics, National Research Council of Canada (Montreal, QC)

Clearing Discovery Information Bottlenecks

Congress Hall G

The promise of genomic and proteomic tools to lower R&D costs, speed-up discovery, lead identification and validation have yet to be fully realized. This session will examine how genomics, proteomics and system biology are being applied, strategies to overcome information bottlenecks and the next generation of tools.

Moderator:
Mr. Sal P. Causi, Business Development Executive, Life Sciences, IBM Canada (Markham, ON)

- From Information & Raw Data To Context-Specific Biological Models
  Dr. Francois Iris, President and Chief Scientific Officer, Bio-Modeling Systems (Paris, France)
- Project Cybercell: Computational Challenges to Cellular Modeling
  Dr. David Wishart, Professor, University of Alberta Institute of Biomolecular Design (Edmonton, Alberta)
- Digital Disease: A Systems Biology Approach to Drug Discovery
  Mr. Colin Hill, Chief Executive Officer and Co-Founder, Gene Network Sciences (Ithaca, N.Y.)
- eNovator
  Richard O’Rourke, Chief Executive Officer, KineMatik (Togher Cork, Ireland)